Wikipedia:Articles for deletion/Oragen


 * The following discussion is an archived debate of the proposed deletion of the article below. Please do not modify it. Subsequent comments should be made on the appropriate discussion page (such as the article's talk page or in a deletion review).  No further edits should be made to this page.

The result was redirect to Rintatolimod.  Sandstein  12:54, 18 July 2018 (UTC)

Oragen

 * – ( View AfD View log  Stats )

Does not pass WP:GNG. Natureium (talk) 19:28, 10 July 2018 (UTC)
 * Keep. Every chemical compound has at least one reference, and Google Scholar lists https://nyaspubs.onlinelibrary.wiley.com/doi/abs/10.1111/j.1749-6632.1993.tb35938.x and one other. Since there aren't more references than these, either a different name is in current use or research into them has been abandoned, but once notable, always notable. Eastmain (talk • contribs) 20:47, 10 July 2018 (UTC)
 * Note: This discussion has been included in the list of Science-related deletion discussions. Thanks,L3X1  ◊distænt write◊  22:07, 10 July 2018 (UTC)


 * Redirect to Rintatolimod - Oragen® is just an oral-delivery formulation of Ampligen®, the proprietary name for Rintatolimod ("Hemispherx has also developed an oral version of the drug (Oragen®), which is undergoing preclinical evaluation." ). We don't need a separate page for an alternative formulation of the same drug (particularly given that it was in preclinical trials in 1993 and still in preclinical trials in 2004, making me doubt it ever progressed beyond that point).  There can be no question of the mentions I have found providing independent notability - most of what I am finding originates with Hemispherx. I would suggest 'merge' but our existing article doesn't have anything worth merging, and we actually already refer to Oragen in the last sentence of the rintatolimod article, just not by name. [As an aside, it looks to me like parts of the rintatolimod article rely too much on company-generated material.] Agricolae (talk) 23:00, 10 July 2018 (UTC)
 * I think Hemispherx Biopharma should be redirected there too. The existing article consists of WP:ROUTINE business reporting, and stories about Ampligen®/Rintatolimod. As best I can tell, this is the equivalent of WP:ONEEVENT, that the company's sole claim to notability is this drug. Agricolae (talk) 23:16, 10 July 2018 (UTC)
 * Nominated separately at Articles for deletion/Hemispherx Biopharma Daask (talk) 15:56, 11 July 2018 (UTC)
 * Note: This discussion has been included in the list of Technology-related deletion discussions. Hhkohh (talk) 02:52, 11 July 2018 (UTC)
 * Note: This discussion has been included in the list of United States of America-related deletion discussions. Hhkohh (talk) 02:52, 11 July 2018 (UTC)


 * Redirect to Rintatolimod per . Daask (talk) 15:41, 11 July 2018 (UTC)
 * Note: This discussion has been included in the list of Medicine-related deletion discussions. Agricolae (talk) 15:50, 11 July 2018 (UTC)


 * Redirect though a delete might be reasonable. I don't see secondary coverage, though some journal articles I can't read may qualify.  I'm not sure this is more notable than (several) companies of this name. The article's claim They are undergoing pre-clinical (in-vitro) trials is almost certainly inaccurate at this time. power~enwiki ( π,  ν ) 18:58, 17 July 2018 (UTC)


 * The above discussion is preserved as an archive of the debate. Please do not modify it. Subsequent comments should be made on the appropriate discussion page (such as the article's talk page or in a deletion review). No further edits should be made to this page.